Stockscreener 앱 받기
121.75
2.75%
3.315
전일 마감가:
$118.44
열려 있는:
$116.06
하루 거래량:
3.64M
Relative Volume:
0.54
시가총액:
$151.04B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
24.22
EPS:
5.0273
순현금흐름:
$9.37B
1주 성능:
+0.63%
1개월 성능:
+9.64%
6개월 성능:
+14.23%
1년 성능:
+37.02%
1일 변동 폭
$114.02
$121.91
1주일 범위
$114.02
$121.91
52주 변동 폭
$86.08
$124.61
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.73 | 146.96B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
847.54 | 757.06B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.25 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.26 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
122.69 | 235.26B | 54.45B | 14.42B | 16.89B | 7.333 |
|
MRK
Merck Co Inc
|
84.67 | 215.51B | 63.43B | 16.42B | 14.72B | 6.4861 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com
Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st
Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com
Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus
Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus
Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener
Gilead 3rd-qtr EPS beats expectations - The Pharma Letter
GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus
Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative
HOOKIPA Pharma (OTC: HOOK) closes sale of HB-400 and HB-500 program assets to Gilead - Stock Titan
Gilead Still Hungry For Deals as HIV Portfolio Grows, Veklury Crashes - BioSpace
Amalgamated Bank Buys 22,916 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating - MarketScreener
JPMorgan Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating - MarketScreener
RBC Capital Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Sector Perform Rating - MarketScreener
Arkadios Wealth Advisors Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030 - Benzinga
Jennison Associates LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Announces Third Quarter 2025 Financial Results - BioSpace
Gilead Sciences Reports Strong Q3 2025 Results - TipRanks
Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ... - Yahoo Finance
Gilead Sciences: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks
Gilead Sciences (GILD) Reports Strong Q3 2025 Performance - GuruFocus
Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Str - GuruFocus
Cell therapy sales dip 11% for Gilead, as HIV franchise drives quarter - Endpoints News
Gilead Sciences’ HIV Drug Sales Lead A Strong Quarter - Finimize
Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum - MSN
Gilead Sciences Lifts Forecast After Topping Earnings Expectations - Finimize
Gilead Q3 2025 slides: HIV strength drives guidance raise, new products gain traction - Investing.com Nigeria
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 10,000 Shares of Stock - MarketBeat
Earnings call transcript: Gilead Sciences Q3 2025 beats expectations, stock steady - Investing.com
Transcript : Gilead Sciences, Inc., Q3 2025 Earnings Call, Oct 30, 2025 - MarketScreener
The Most Anticipated Gilead Drug Lagged Massive Expectations - Investor's Business Daily
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations - MSN
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Gilead posts higher profit on demand for HIV drugs, but overall sales dip - Reuters
Gilead Sciences (GILD) Surpasses Q3 Earnings Expectations - GuruFocus
Gilead Sciences (GILD) Shares Fall Despite Beating Q3 Expectatio - GuruFocus
Gilead Sciences Inc. Profit Advances In Q3 - Nasdaq
Gilead Sciences (GILD) Surpasses Q3 2025 Earnings Expectations - GuruFocus
Gilead Sciences Inc (GILD) Q3 2025 Earnings: EPS of $2.43 Beats Estimate, Revenue Reaches $7.8 Billion - GuruFocus
Gilead drops despite narrowing 2025 outlook ranges on weak Veklury sales - MSN
Earnings Snapshot: Gilead beats Q3 results but Veklury drags product sales - MSN
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations - Yahoo Finance
Gilead Sciences Q3 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Adjusted - MarketScreener
Mich. Top Court Upholds Gilead Immunity In COVID Drug Case - Law360
(GILD) Gilead Updates Full Year 2025 Product Sales Outlook Range To $28.40 Billion$28.70 Billion, vs. FactSet Est $28.71 Billion - MarketScreener
Gilead Sciences misses on revenue guidance estimates, shares drop 4% - Investing.com
(GILD) Gilead Sciences Updates Full Year 2025 Adjusted EPS Outlook Range To $8.05$8.25, vs. FactSet Est of $8.04 - MarketScreener
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.12%
자본화:
|
볼륨(24시간):